| 600.65 -10.92 (-1.79%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 735.47 | 1-year : | 859.03 |
| Resists | First : | 629.69 | Second : | 735.47 |
| Pivot price | 603.98  |
|||
| Supports | First : | 588.75 | Second : | 563.45 |
| MAs | MA(5) : | 613.07 |
MA(20) : | 598.58 |
| MA(100) : | 507.78 |
MA(250) : | 522.7 |
|
| MACD | MACD : | 14.7 |
Signal : | 16.5 |
| %K %D | K(14,3) : | 67.1 |
D(3) : | 74 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 677.9 | Low : | 373 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MEDP ] has closed above bottom band by 43.5%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 610.51 - 613.98 | 613.98 - 617.74 |
| Low: | 589.59 - 593.46 | 593.46 - 597.66 |
| Close: | 593.38 - 600.08 | 600.08 - 607.36 |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Fri, 28 Aug 2026
Medpace Holdings (MEDP) director exercises options, sells 3,858 shares - Stock Titan
Thu, 27 Aug 2026
Medpace (MEDP) CEO sells 4,673 shares near $620 in open-market trades - Stock Titan
Wed, 26 Aug 2026
If You Invested $1000 In Medpace Holdings Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Wed, 26 Aug 2026
What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock - The Globe and Mail
Wed, 26 Aug 2026
Medpace CEO Sells 15,978 Shares for $10 Million - Intellectia AI
Tue, 25 Aug 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Stockholders to Connect - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 28 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 19.7 (%) |
| Held by Institutions | 91.5 (%) |
| Shares Short | 1,750 (K) |
| Shares Short P.Month | 2,130 (K) |
| EPS | 17.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.55 |
| Profit Margin | 17.6 % |
| Operating Margin | 20.7 % |
| Return on Assets (ttm) | 20.1 % |
| Return on Equity (ttm) | 162.1 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 72.01 |
| Sales Per Share | 99.6 |
| EBITDA (p.s.) | 21.89 |
| Qtrly Earnings Growth | 37 % |
| Operating Cash Flow | 753 (M) |
| Levered Free Cash Flow | 510 (M) |
| PE Ratio | 35.31 |
| PEG Ratio | 3.3 |
| Price to Book value | 38.62 |
| Price to Sales | 6.03 |
| Price to Cash Flow | 22.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|